Trials / Completed
CompletedNCT01011738
An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,842 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational, non-interventional cohort study will evaluate predictors of response in patients with chronic hepatitis B receiving standard of care Pegasys therapy. Efficacy and safety parameters will also be evaluated. Patients included in the study will be followed for the duration of their treatment and for up to 3 years thereafter.
Conditions
Timeline
- Start date
- 2009-04-11
- Primary completion
- 2014-11-18
- Completion
- 2014-11-18
- First posted
- 2009-11-11
- Last updated
- 2017-04-10
- Results posted
- 2016-04-08
Locations
249 sites across 27 countries: Austria, Bahrain, Bangladesh, Bosnia and Herzegovina, Bulgaria, China, Egypt, France, Germany, Hong Kong, India, Indonesia, Ireland, Jordan, Lebanon, Morocco, New Zealand, North Macedonia, Pakistan, Poland, Portugal, Romania, Saudi Arabia, South Korea, Thailand, United Arab Emirates, United Kingdom
Source: ClinicalTrials.gov record NCT01011738. Inclusion in this directory is not an endorsement.